GlassScriptPhysician profile
Clifford C Sebastian
NPI 1164409538
$3,436.55
in general payments reported to CMS, 2019-2025
26 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $349 · 2021: $483 · 2022: $664 · 2023: $373 · 2024: $468 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $802.16 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $514.97 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $366.09 | 2019-2025 | |
| Boston Scientific Corporation | $357.23 | 2019-2025 | Watchman Flx, Watchman Access System, Watchman |
| Merck Sharp & Dohme LLC | $254.61 | 2022-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $163.18 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $134.26 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $120.63 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $79.77 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $73.96 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $64.50 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.31 | 2019-2024 | Lifevest |
| Althera Pharmaceuticals LLC | $60.54 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $54.78 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $44.64 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $42.14 | 2019-2020 | |
| Biosense Webster, INC. | $37.80 | 2020 | |
| Bard Peripheral Vascular, INC. | $35.72 | 2021 | |
| Abiomed | $32.94 | 2022 | |
| Allergan, INC. | $25.66 | 2019 | |
| Heartflow, INC. | $23.50 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.04 | 2025 | |
| Bridgebio Pharma, INC. | $19.00 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $15.75 | 2025 | Assure Wcd |
| Gilead Sciences, INC. | $14.98 | 2021 | |
| Chiesi USA, INC. | $14.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifford Sebastian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.